PINOT BIO
Pinot Bio is a biotechnology company that specializes in developing new generation anticancer treatments.
PINOT BIO
Social Links:
Industry:
Biotechnology Medical Device Oncology Therapeutics
Founded:
2017-01-01
Address:
Seongnam, Kyonggi-do, South Korea
Country:
South Korea
Website Url:
http://www.pinotbio.com
Total Employee:
11+
Status:
Active
Total Funding:
39.9 B KRW
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Tag Manager Google Analytics LetsEncrypt Global Site Tag Mobile Non Scaleable Content DoubleClick.Net US Privacy User Signal Mechanism
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
VintaBio
VintaBio is a life sciences company that offers cell and gene therapy manufacturing services.
Current Employees Featured
Investors List
Lotte Group
Lotte Group investment in Corporate Round - Pinot Bio
ST Pharm
ST Pharm investment in Venture Round - Pinot Bio
Stick Ventures
Stick Ventures investment in Venture Round - Pinot Bio
IMM Investment
IMM Investment investment in Venture Round - Pinot Bio
Quantum Ventures Korea
Quantum Ventures Korea investment in Venture Round - Pinot Bio
Aion Investment Management
Aion Investment Management investment in Venture Round - Pinot Bio
Ulmus Investment
Ulmus Investment investment in Venture Round - Pinot Bio
KB Securities
KB Securities investment in Venture Round - Pinot Bio
Stone Bridge Ventures
Stone Bridge Ventures investment in Series B - Pinot Bio
KB Investment
KB Investment investment in Series B - Pinot Bio
Official Site Inspections
http://www.pinotbio.com Semrush global rank: 13.42 M Semrush visits lastest month: 92
- Host name: 183.111.169.45
- IP address: 183.111.169.45
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "Pinot Bio"
피노바이오 - pinotbio.com
Address. 8F, 156, Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea. Fax. 031-8064-1303; E-mail [email protected]See details»
Pinot Bio - Crunchbase Company Profile & Funding
Pinot Bio is a biotechnology company that specializes in developing new generation anticancer treatments.See details»
피노바이오 - pinotbio.com
Our mission is to create real hopes through innovative new drug developmentsSee details»
PinotBio Company Profile 2024: Valuation, Funding
PinotBio General Information Description. Developer of anticancer drugs designed to treat cancer patients. The company's drugs help to overcome refractory, relapsed cancer, glaucoma and other incurable diseases, enabling …See details»
Pinotbio (fka Bionetix) - VentureRadar
PinotBio, Inc. is a development stage biotech focusing on the development of innovative small molecule based new drugs. With the aim of providing novel solutions to patients with high …See details»
PinotBio - Products, Competitors, Financials, Employees, …
About PinotBio. PinotBio is a biotechnology company focused on developing novel anticancer treatments. The company's main offerings include a next-generation ADC platform technology …See details»
Pinot Bio - Updates, News, Events, Signals & Triggers - Crunchbase
PharmiWeb.com — Aptamer Group and PinotBio extend collaboration for the development of Optimer®-drug conjugates Funding Round • Mar 22, 2021 Pinot Bio raised ₩6,000,000,000 / …See details»
피노바이오 - pinotbio.com
Pinotbio conducts R&D on an ADC platform, a best-in-class targeted anticancer drug, and a glaucoma medicine. We are a biotech company developing new treatments for patients …See details»
Pinotbio starts developing Trop-2 ADC’s GMP …
May 23, 2023 Pinotbio, which is jointly developing antibody-drug conjugate (ADC) drugs with Celltrion and Lotte Biologics, has begun developing a manufacturing process for Trop-2-targeted ADCs.Pinotbio said Tuesday that it …See details»
Pinotbio, Inc. (Pinotbio, Inc.) - 药物管线_专利_临床试验_投融营收_ …
了解Pinotbio, Inc. (Pinotbio, Inc.)公司的药物管线，治疗领域，技术平台，以及它的2项临床试验, 2篇新闻和1篇文献，疾病领域:肿瘤，血液及淋巴系统疾病，内分泌与代谢疾病，神经系统疾 …See details»
Pinotbio inks $250 million license-out deal with ConjugateBio for …
Dec 21, 2023 Pinotbio will supply drugs and linkers, and ConjugateBio will be responsible for target selection, antibody development, synthesis, and evaluation. According to market …See details»
Aptamer Group and PinotBio collaborate to develop new …
02/06/2021. Aptamer Group Limited, the developer of Optimer ® Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, today …See details»
Pinotbio, Conjugatebio strike $250M deal for 10 ADC targets
Jan 2, 2024 South Korean biotech Pinotbio Co. Ltd. inked a $250 million (₩320 billion) licensing deal with Princeton, N.J.-based Conjugatebio Inc. to develop 10 antibody-drug conjugate …See details»
피노바이오 - pinotbio.com
2017~PRESENT Growth and Leap of Pinotbio. 2024. 10 Strategic Investment (Celltrion, KR) 09 Achieved first milestone on ADC platform transferred to Celltrion 08 Started the phase 1b/2a of …See details»
“If the compound can be made, Symeres will undoubtedly find out …
Nov 28, 2023 Pinotbio and Symeres first met at the BioFit conference held at Strasbourg in 2017. We were Bionetix at that time (we changed our name in 2020) and Symeres was …See details»
Aptamer Group and PinotBio collaborate to develop new …
Jun 2, 2021 Please use one of the following formats to cite this article in your essay, paper or report: APA. Aptamer Group. (2021, June 02). Aptamer Group and PinotBio collaborate to …See details»
피노바이오 - pinotbio.com
The CEO of Pinotbio Co., Ltd. Pinotbio has been developing innovative new drugs for incurable diseases, such as Resistant/recurrent cancer, for which there is no suitable treatment despite …See details»
Aptamer Group and PinotBio extend collaboration for the …
May 23, 2022 PinotBio’s linker-payload platform has shown the potential to overcome tumour resistance and safety concerns even at relatively high doses in non-human primate …See details»
피노바이오 - pinotbio.com
Next Generation ADC Platform. PINOT-ADC™ is a next-generation ADC anticancer drug platform technology that uses an independent drug (Payload) and linker that overcome the limitations …See details»